Sana Biotechnology Inc

NASDAQ:SANA

3.27

+0.16 (+5.14%)

7:09:02 PM EDT: $3.40 +0.13 (+3.98%)

Products

Sana Biotechnology Announces FDA Nod For Human Clinical Trials For Car T Therapy For B-Cell Malignancies

Published: 01/26/2023 22:31 GMT

Sana Biotechnology Inc (SANA) - Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, a Hypoimmune-modified, Cd19-targeted Allogeneic Car T Therapy for Patients With B-cell Malignancies.
Sana Biotechnology Inc - Goal is to Report Initial Sc291 Clinical Data This Year.
Sana Biotechnology Inc - Goal is to Submit a Second Ind From Platform This Year for Sc262.